ABT is uniquely positioned to provide PEGylation services.
ABT has the expertise to work with drugs and biologics with poor solubility, low bioavailability, short half-life, and gastric intolerability. PEGylation of drugs and biologics offers a soluble and safe methodology to improve drug performance.

A modification of biopharmaceutical with Polyethylene glycol (PEG) can:

• Increase the hydrodynamic radius
• Reduce immunogenicity
• Decelerate renal excretion
• Improve stability (proteolysis/temperature)

ABT accesses a deep catalogue of proprietary monodispersed PEG molecules.  ABT’s deep expertise in protein conjugation and protein optimization can help you develop a PEG application to suit your research program needs.  ABT also provides protein expression, stabilization, protein characterization, assay development, and protein conjugation. 

ABT’s PEG capabilities include:

• Both mono and polydispersed PEG
• Various molecular weights
• Techniques to create different hydrodynamic volumes release mechanisms

• PEG with amine, NHS ester, acid, aldehyde, and additional functionality
• Branched alternatives
• Novel and patentable PEG
• Reproducible quality
  

ABT’s PEGylation Development Experience:

1. Non-dispersed PEG and multimerization reagents
2. Customized PEGylation
3. PEGylation process development
4. Customized synthesis of PEG-reagents
5. Production of Proof-of-Concept material
6. Design of PEGylation strategy
7. Selection of chemistry and PEG reagent
8. Purification and characterization